Electromed (ELMD) sees room in underpenetrated bronchiectasis market and high margins
According to TradingView, Electromed highlighted sales expansion and high margins at a presentation, with management expecting double-digit revenue growth.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, Electromed (ELMD) used a presentation to stress an underpenetrated bronchiectasis market in the United States. Its direct-to-patient model supports gross margins in the high 70s percent.
Management plans to expand sales, refine its product market sizing and widen hospital reach. It expects double-digit revenue growth and further operating leverage.
why it matters
For investors, the key point is that the company is betting on a niche segment with limited coverage, and high margins could amplify the effect of revenue growth. These are plans described at a presentation rather than reported results, so actual outcomes remain unknown.
tags
instruments
sources
- ELMD: An underpenetrated lung-care market fuels growth plans, high margins, and operating leverage — TradingView, 20 October 2026 at 22:29 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗